炎症与动脉粥样硬化狭窄或闭塞性疾病关系的研究进展  

Research progress on the relationship between inflammation and arteriosclerotic stenosis or occlusive disease

作　　者：曹启鑫 杨涛[1] 郝斌[1] Cao Qixin;Yang Tao;Hao Bin(Department of Vascular Surgery,the Third Hospital of Shanxi Medical University,Shanxi Bethune Hospital,Shanxi Academy of Medical Sciences,Tongji Shanxi Hospital,Taiyuan 030032,Shanxi,China)

机构地区：[1]山西医科大学第三医院(山西白求恩医院山西医学科学院同济山西医院)血管外科,山西太原030032

出　　处：《血管与腔内血管外科杂志》2024年第7期816-821,共6页Journal of Vascular and Endovascular Surgery

基　　金：山西省面上自然基金项目(201901D111407)。

摘　　要：动脉粥样硬化(AS)狭窄或闭塞性疾病的发病机制复杂,大量的基础研究表明炎症机制在AS的发生、发展阶段发挥着至关重要的作用。尽管临床上针对AS狭窄或闭塞性疾病进行了很好的降脂及抗血小板治疗,但相关不良事件仍有发生,因此,寻找新的治疗靶点至关重要。针对炎症的靶向治疗可以改善这类患者的临床结局,一些药物已经展现出了其应用潜力。本文对炎症与AS狭窄或闭塞性疾病的关系进行系统综述,并讨论抗感染治疗在此类疾病中的应用情况。The pathogenesis of arteriosclerotic stenosis or occlusive disease is complex,and a large number of basic studies have shown that inflammatory mechanisms play a crucial role in the development and progression of atherosclerosis.Although we have performed good lipid-lowering and antiplatelet therapy for arteriosclerotic stenosis or occlusive disease in clinical practice,related adverse events are still occurring,therefore,finding new therapeutic targets is crucial.Targeted therapy for inflammation can improve the clinical outcomes of such patients,and some drugs have shown their application potential.This article reviews the relationship between inflammation and arteriosclerotic stenosis or occlusive disease,and discuss the application of anti-inflammatory therapy in such diseases.

关 键 词：动脉粥样硬化狭窄或闭塞性疾病 炎症机制 靶向治疗 抗感染治疗 

分 类 号：R543[医药卫生—心血管疾病]